The analysis by our unique collaboration indicates that the cancer risk in these relatively
benign early lesions is determined by the number of abnormal clones that has been established in the Barrett's mucosa, rather than by specific gene abnormalities.»
Not exact matches
The predictor accurately differentiated pancreatic cancer,
benign pancreatic
lesions,
early stage pancreatic cancer and healthy tissue.
«The identification and initial validation of a highly accurate 5 - gene pancreatic cancer biomarker panel that can discriminate late and
early stages of pancreatic cancer from normal pancreas and
benign pancreatic
lesions could facilitate
early diagnosis of pancreatic cancer,» said co-senior author Roya Khosravi - Far, PhD, Associate Professor of Pathology at BIDMC.
After demonstrating and independently validating that a 5 - gene pancreatic cancer predictor discriminated between cancerous and healthy tissue, the researchers applied the predictor to datasets that also included
benign lesions of the pancreas, including pancreatitis and
early stage cancer.
When performed in tandem, two molecular biology laboratory tests distinguish, with near certainty, pancreatic
lesions that mimic
early signs of cancer but are completely
benign.